Article Text

Download PDFPDF


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

An authors’ error occurred in this paper by Dr Alagiakrishnan and others (2006;82:101–5). The competing interests statements were not included in the paper. The statements are printed below.

Peter N McCracken: in the past three years I have received grant research support from Pfizer, Eisai, Sanofi-aventis, Lundbeck Canada, Servier Canada, Janssen-Ortho, and Neurochem Inc, Syreon Corporation, and Wyeth. I have served as a consultant for Pfizer, Eisai, Novartis, Lundbeck Canada, and Janssen Ortho. I have been on the Speaker’s Bureau or served in CME programmes with Pfizer, Eisai, Novartis, Lundbeck, and Janssen Ortho. I am not a shareholder in these firms and receive no other financial or material support.

Howard Feldman: in the past three years, I have/have had a financial interest/arrangement or affiliation with the following organisations: grant/research support (external): Pfizer, Eisai, Janssen, Lilly, Astra Zeneca, Sanofi Synthelabo, Glaxo Smith Kline. Consultant: Pfizer, Eisai, Novartis, Janssen, Servier, Sanofi Synthelabo, Glaxo Smith Kline, Myriad, Targacept, Lundbeck, Forest, Axonyx. Speakers’ Bureau, or CME programmes: Pfizer, Eisai, Janssen, Novartis, Forest. For this specific article I have had financial arrangements with Pfizer, Eisai, Novartis, and Janssen as listed above. They are the manufacturers of the acetylcholinesterase inhibitors. Pfizer is also the manufacturer of atorvastatin, a statin that is being investigated in Alzheimer’s disease and for which I have been a consultant.

Kannayiram Alagiakrishnan: in the past three years I have received research support from Janssen-Ortho.